OPTImizing MIltefosine Treatment for Cutaneous LEISHmaniasis Patients
The OPTIMILEISH trial aims to optimize miltefosine treatment for cutaneous leishmaniasis (CL) patients, particularly focusing on dosing strategies for children and understanding parasite dynamics. The study is being conducted by the Institute of Tropical Medicine in collaboration with several Ethiopian and international institutions.
Indication: Cutaneous Leishmaniases
Modality: small molecule
Target: Cutaneous Leishmaniasis
Sponsor: Institute of Tropical Medicine, Belgium
Source URL: ClinicalTrials.gov
Source updated: Jul 23, 2024
Ingested: May 23, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Cutaneous Leishmaniasis
View original source fields
Condition raw: Cutaneous Leishmaniases
Condition normalized: Cutaneous Leishmaniases
Modality raw: Cutaneous Leishmaniases
Modality normalized: small molecule
Target raw: Cutaneous Leishmaniasis
Target normalized: Cutaneous Leishmaniasis